^(188)Re标记多肽的研究进展  

Progress on studying ^(188)Re labeled peptides

作　　者：张秀利[1] 张春富[1] 李俊玲[1] 曹金全[1] 尹端沚[1] 汪勇先[1] 

机构地区：[1]中国科学院上海原子核研究所,上海201800

出　　处：《核技术》2002年第7期587-592,共6页Nuclear Techniques

基　　金：中国科学院创新工程领域前沿项目 (90 2 0 0 1 54)资助

摘　　要：阐述了多肽放射性药物的优点 ,188Re -高铼酸钠的性质 ,188Re标记多肽的方法及其研究进展 。Because small peptides have many advantages than monoclonal antibodies (MoAbs), radio-labeled peptides have emerged as an important class of radiopharmaceuticals and are the subject of doing nuclear medicine research. 188 Re (E β,max =2.11MeV; E γ=155keV; T 1/2 =16.9h) is an attrative therapeutic radionuclide and conveniently obtained on demand by elution from the 188 W/ 188 Re generator system. This article reviewed the physical and chemical properties, nuclear characters and biological behavior in vivo and vitro of the 188 Re. The approaches (direct labeling approach, preconjugate labeling approach, postconjugate labeling approach) to the labeling of peptides radiopharmceuticals were discussed and recent progress of the 188 Re labeled peptides (RC-160, VIP, et al ) were given. The forecasts of 188 Re labeled peptide radiopharmceuticals in their development were considered.

关 键 词：^188RE 多肽 标记方法 多肽放射性药物 

分 类 号：R977.6[医药卫生—药品] TL92[医药卫生—药学]